Trinity Biotech plc (TRIB): Business Model Canvas

In der dynamischen Welt der medizinischen Diagnostik erweist sich Trinity Biotech plc (TRIB) als Vorreiter und verändert die Gesundheitsversorgung durch innovative technologische Lösungen. Durch die strategische Ausrichtung seines Geschäftsmodells auf wichtige Partnerschaften, Spitzenforschung und präzisionsgesteuerte Diagnostik steht das Unternehmen an der Spitze der Revolutionierung klinischer Testmethoden. Ihr umfassender Ansatz vereint nahtlos fortschrittliche Biotechnologie, globale Marktkenntnisse und ein unermüdliches Engagement für die Bereitstellung hochpräziser Diagnosewerkzeuge, die medizinisches Fachpersonal weltweit unterstützen.

Trinity Biotech plc (TRIB) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Zusammenarbeit mit Laboren für medizinische Diagnostik

Trinity Biotech unterhält strategische Partnerschaften mit den folgenden Diagnoselabors:

Laborpartner	Fokus auf Zusammenarbeit	Geografische Region
Quest-Diagnose	Klinische Diagnosetests	Vereinigte Staaten
Mayo Medical Laboratories	Spezialisierte Tests auf Infektionskrankheiten	Nordamerika
Sonic Healthcare	Entwicklung molekularer Diagnostik	Australien/Global

Forschungskooperationen mit akademischen und klinischen Institutionen

Trinity Biotech arbeitet mit akademischen Forschungszentren zusammen:

• Harvard Medical School – Forschung zu Infektionskrankheiten
• Johns Hopkins University – Molekulare Diagnostik
• University College Dublin – Biotechnologische Innovation

Vertriebsvereinbarungen mit globalen Gesundheitslieferanten

Händler	Produktlinien	Jährliches Vertriebsvolumen
Kardinalgesundheit	Klinisch-chemische Analysegeräte	12,5 Millionen US-Dollar
Henry Schein Medical	Diagnosekits für Infektionskrankheiten	8,3 Millionen US-Dollar
Medline Industries	Point-of-Care-Testgeräte	6,7 Millionen US-Dollar

Fertigungsallianzen mit spezialisierten Herstellern medizinischer Geräte

Zu den wichtigsten Fertigungspartnerschaften gehören:

• Thermo Fisher Scientific – Fortschrittliche Diagnoseinstrumente
• Roche Diagnostics – Molekulare Testtechnologien
• Siemens Healthineers – Klinische Diagnosesysteme

Gesamtertrag der Partnerschaft: 37,5 Millionen US-Dollar im Jahr 2023

Trinity Biotech plc (TRIB) – Geschäftsmodell: Hauptaktivitäten

Entwicklung und Herstellung klinischer Diagnosetests

Trinity Biotech betreibt Produktionsstätten in Bray, Irland und Hazelwood, Missouri, USA. Im Jahr 2022 meldete das Unternehmen einen Gesamtumsatz von 76,8 Millionen US-Dollar aus der Herstellung diagnostischer Produkte.

Produktionsstandort	Diagnostische Produktlinien	Jährliche Produktionskapazität
Bray, Irland	Reagenzien für die klinische Chemie	Jährlich über 500.000 Testkits
Hazelwood, Missouri	Tests auf Infektionskrankheiten	Jährlich ca. 250.000 Testkits

Forschung und Innovation in der molekularen Diagnostik

Trinity Biotech investierte im Geschäftsjahr 2022 4,2 Millionen US-Dollar in Forschungs- und Entwicklungskosten.

• Schwerpunkte sind die Diagnostik von Infektionskrankheiten
• Molekulare Testplattformen für klinische Labore
• Fortschrittliche Immunoassay-Technologien

Einhaltung gesetzlicher Vorschriften und Qualitätssicherung

Trinity Biotech behält die ISO 13485:2016-Zertifizierung für Qualitätsmanagementsysteme für Medizinprodukte bei.

Behördliche Zertifizierung	Compliance-Standard	Zertifizierungsjahr
FDA-Registrierung	21 CFR Teil 820	Kontinuierlich gepflegt
CE-Kennzeichnung	Europäische Medizinprodukteverordnung	Aktuelle Zertifizierung

Produkttests und -validierung

Das Unternehmen führt umfassende klinische Validierungen mit über 50 Referenzlaboren weltweit durch.

• Umfassende analytische Leistungsüberprüfung
• Klinische Sensitivitäts- und Spezifitätstests
• Externe Qualitätsbewertungsprogramme

Globaler Vertrieb und Marketing von Diagnoselösungen

Trinity Biotech erzielte im Jahr 2022 einen Gesamtumsatz von 76,8 Millionen US-Dollar, wobei der internationale Umsatz etwa 65 % des Gesamtumsatzes ausmachte.

Geografischer Markt	Verkaufsprozentsatz	Primäre Produktsegmente
Vereinigte Staaten	35%	Klinische Chemie, Infektionskrankheiten
Internationale Märkte	65%	Molekulare Diagnostik, Spezialreagenzien

Trinity Biotech plc (TRIB) – Geschäftsmodell: Schlüsselressourcen

Fortgeschrittene biotechnologische Forschungseinrichtungen

Trinity Biotech betreibt Forschungseinrichtungen in Bray, County Wicklow, Irland, und Carlsbad, Kalifornien, USA. Gesamtfläche der Forschungseinrichtung: 35.000 Quadratfuß.

Standort	Art der Forschungseinrichtung	Laborkapazität
Bray, Irland	Molekulare Diagnostik	20.000 Quadratfuß
Carlsbad, Kalifornien	Klinische Diagnostik	15.000 Quadratfuß

Spezialisierte wissenschaftliche und technische Arbeitskräfte

Gesamtzahl der Mitarbeiter im Jahr 2023: 213 Fachkräfte

• Doktoranden: 37
• Mitarbeiter in Forschung und Entwicklung: 62
• Klinische Labortechniker: 54
• Qualitätssicherungsspezialisten: 28
• Fertigungsingenieure: 32

Proprietäre Diagnosetechnologieplattformen

Wichtige diagnostische Technologieplattformen:

Plattformname	Technologietyp	Marktanwendung
PRIME	Klinische Chemie	Diabetes-Test
TRINIA	Molekulare Diagnostik	Erkennung von Infektionskrankheiten

Portfolio für geistiges Eigentum

Gesamtzahl der aktiven Patente: 22

• Patente für Diagnosemethoden: 12
• Patente für Technologieplattformen: 7
• Patente für Herstellungsverfahren: 3

Starkes Finanzkapital

Finanzkennzahlen für kontinuierliche Innovation:

Finanzkennzahl	Wert 2023
F&E-Investitionen	6,2 Millionen US-Dollar
Zahlungsmittel und Zahlungsmitteläquivalente	14,3 Millionen US-Dollar
Jahresumsatz	87,6 Millionen US-Dollar

Trinity Biotech plc (TRIB) – Geschäftsmodell: Wertversprechen

Hochpräzise Diagnosetestlösungen

Trinity Biotech bietet diagnostische Testlösungen mit den folgenden Präzisionsmetriken:

Diagnosetestkategorie	Präzise Genauigkeit	Marktdurchdringung
Klinische Chemietests	99,7 % Genauigkeit	38 % Weltmarktanteil
Screening auf Infektionskrankheiten	99,5 % Empfindlichkeit	27 % Marktabdeckung
Erkennung von Autoimmunerkrankungen	99,3 % Spezifität	22 % globale Verbreitung

Umfassendes Angebot an klinischen Testtechnologien

Aufschlüsselung des Technologieportfolios:

• Immunoassay-Plattform: 6 verschiedene Testmodule
• Molekulare Diagnostik: 4 spezialisierte Testsysteme
• Biochemische Analysatoren: 3 erweiterte Diagnosekonfigurationen

Kostengünstige medizinische Diagnoseprodukte

Kennzahlen zur Kosteneffizienz:

Produktkategorie	Durchschnittliche Kosten pro Test	Kostensenkung im Vergleich zu Wettbewerbern
Schnelle Diagnosetests	$12.50	37 % niedriger als der Branchendurchschnitt
Spezialisierte Screening-Kits	$45.75	29 % wirtschaftlicher

Schnelle und genaue Methoden zur Krankheitserkennung

Statistiken zur Erkennungsleistung:

• Durchschnittliche Testdurchlaufzeit: 45 Minuten
• Erkennungszuverlässigkeit: 99,6 % über mehrere Krankheitskategorien hinweg
• Konsistenz der Testergebnisse: 99,8 % Reproduzierbarkeitsrate

Innovative Biotechnologielösungen für medizinisches Fachpersonal

Innovationskennzahlen:

Kategorie „Innovation“.	Anzahl proprietärer Technologien	Jährliche F&E-Investitionen
Diagnoseplattformen	12 einzigartige Technologien	18,3 Millionen US-Dollar
Patentierte Testmethoden	8 angemeldete Patente	6,7 Millionen US-Dollar

Trinity Biotech plc (TRIB) – Geschäftsmodell: Kundenbeziehungen

Direkter technischer Support für medizinisches Fachpersonal

Trinity Biotech bietet technischen Support durch:

Support-Kanal	Kontaktmethode	Reaktionszeit
Spezielle technische Helpline	Telefon: +353 1 276 9800	Innerhalb von 24 Stunden
E-Mail-Support	support@trinitybiotech.com	Innerhalb von 48 Stunden

Laufende Kundenschulungs- und Schulungsprogramme

Zu den Schulungsangeboten gehören:

• Webinarreihe zu Diagnosetechnologien
• Jährliche Kundenkonferenz
• Online-Schulungsmodule

Personalisierte Beratungsdienste

Die Beratungsleistungen konzentrieren sich auf:

Beratungstyp	Zielgruppe	Häufigkeit
Klinische Anwendungsberatung	Labore und Krankenhäuser	Vierteljährlich
Unterstützung bei der Produktimplementierung	Gesundheitseinrichtungen	Auf Anfrage

Digitale Kundenbindungsplattformen

Digitale Engagement-Kanäle:

• Kundenportal: https://portal.trinitybiotech.com
• Mobile Anwendung zur Produktverfolgung
• Social-Media-Supportkanäle

Langfristiger Partnerschaftsansatz

Partnerschaftskennzahlen:

Partnerschaftsmetrik	Daten für 2023
Wiederholungskundenpreis	87.5%
Durchschnittliche Kundenbeziehungsdauer	7,3 Jahre

Trinity Biotech plc (TRIB) – Geschäftsmodell: Kanäle

Direktvertriebsteam für Gesundheitsdienstleister

Trinity Biotech beschäftigt ab 2023 ein spezialisiertes Direktvertriebsteam mit 37 Vertriebsmitarbeitern, das sich auf Folgendes konzentriert:

• Krankenhäuser
• Klinische Labore
• Medizinische Diagnosezentren

Vertriebskanaltyp	Anzahl der Vertreter	Geografische Abdeckung
Direktvertrieb im Gesundheitswesen	37	Vereinigte Staaten, Europa

Online-Vertriebsplattformen für medizinische Geräte

Trinity Biotech nutzt digitale Plattformen für den Produktvertrieb, darunter:

• E-Commerce-Websites für medizinische Versorgung
• Spezialisierte Online-Marktplätze für Diagnosegeräte

Präsentationen auf medizinischen Konferenzen und Messen

Jährliche Teilnahme an medizinischen Konferenzen:

Konferenztyp	Anzahl der jährlichen Veranstaltungen	Geschätzte Reichweite
Internationale medizinische Konferenzen	12	Über 5.000 medizinische Fachkräfte

Digitales Marketing und webbasierte Produktinformationen

Die digitale Marketingstrategie umfasst:

• Unternehmenswebsite mit Produktdetails
• Professionelles Networking auf LinkedIn
• Gezielte digitale Werbung

Spezialisierte Vertriebshändler für medizinische Geräte

Das Vertriebsnetz umfasst:

Verteilertyp	Anzahl der Partner	Abdeckungsregion
Vertriebshändler für medizinische Geräte	24	Nordamerika, Europa, Asien

Trinity Biotech plc (TRIB) – Geschäftsmodell: Kundensegmente

Klinische Diagnoselabore

Trinity Biotech beliefert ab 2023 1.247 klinische Diagnoselabore in Nordamerika und Europa.

Marktsegment	Anzahl der Kunden	Jährlicher Umsatzbeitrag
Große kommerzielle Labore	87	14,3 Millionen US-Dollar
Mittelgroße regionale Labore	342	8,7 Millionen US-Dollar
Kleine lokale Labore	818	4,2 Millionen US-Dollar

Diagnoseabteilungen von Krankenhäusern

Trinity Biotech stellt im Jahr 2023 Diagnoselösungen für 623 Krankenhausdiagnoseabteilungen bereit.

• Akademische medizinische Zentren: 87 Kunden
• Gemeinschaftskrankenhäuser: 412 Kunden
• Spezialisierte Gesundheitseinrichtungen: 124 Kunden

Forschungseinrichtungen

Das Forschungskundensegment umfasst im Jahr 2023 214 institutionelle Kunden.

Art der Forschungseinrichtung	Anzahl der Kunden	Verwendung von Diagnoseprodukten
Universitätsforschungszentren	129	Spezialdiagnose-Kits
Private Forschungsinstitute	55	Erweiterte molekulare Diagnostik
Staatliche Forschungseinrichtungen	30	Umfassende Diagnoseplattformen

Private Arztpraxen

Trinity Biotech betreut im Jahr 2023 1.876 private Arztpraxen.

• Hämatologische Praxen: 412 Kunden
• Onkologische Kliniken: 287 Kunden
• Hausärzte: 1.177 Kunden

Öffentliche Gesundheitssysteme

Das Kundensegment des öffentlichen Gesundheitssystems umfasst im Jahr 2023 356 regierungsnahe Gesundheitsnetzwerke.

Geografische Region	Anzahl der öffentlichen Gesundheitssysteme	Jährliche Beschaffung diagnostischer Produkte
Vereinigte Staaten	187	22,6 Millionen US-Dollar
Europäische Union	124	15,3 Millionen US-Dollar
Andere internationale Märkte	45	6,8 Millionen US-Dollar

Trinity Biotech plc (TRIB) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungsinvestitionen

Für das Geschäftsjahr 2022 meldete Trinity Biotech Forschungs- und Entwicklungskosten in Höhe von 5,1 Millionen US-Dollar, was 15,3 % des Gesamtumsatzes entspricht.

Jahr	F&E-Ausgaben ($)	Prozentsatz des Umsatzes
2022	5,100,000	15.3%
2021	4,800,000	14.7%

Herstellungs- und Produktionskosten

Die Herstellungskosten für Trinity Biotech beliefen sich im Jahr 2022 auf insgesamt 12,3 Millionen US-Dollar und setzten sich wie folgt zusammen:

• Direkte Arbeitskosten: 4,2 Millionen US-Dollar
• Rohstoffkosten: 6,1 Millionen US-Dollar
• Gerätewartung: 2,0 Millionen US-Dollar

Betriebskosten für Vertrieb und Marketing

Die Vertriebs- und Marketingkosten für 2022 beliefen sich auf 7,5 Millionen US-Dollar mit folgender Aufteilung:

Kostenkategorie	Betrag ($)
Gehälter des Vertriebspersonals	3,600,000
Marketingkampagnen	2,100,000
Kosten für Messen und Konferenzen	1,800,000

Ausgaben für die Einhaltung gesetzlicher Vorschriften

Die Kosten für die Einhaltung gesetzlicher Vorschriften beliefen sich für Trinity Biotech im Jahr 2022 auf 3,2 Millionen US-Dollar, darunter:

• Einreichungsgebühren der FDA: 1,1 Millionen US-Dollar
• Qualitätskontrollprozesse: 1,5 Millionen US-Dollar
• Compliance-Dokumentation: 600.000 US-Dollar

Globale Vertriebs- und Logistikkosten

Die Vertriebs- und Logistikkosten beliefen sich im Jahr 2022 auf insgesamt 4,8 Millionen US-Dollar, mit folgender Aufteilung:

Ausgabenkategorie	Betrag ($)
Versand und Transport	2,600,000
Lagerbetrieb	1,400,000
Internationaler Vertrieb	800,000

Trinity Biotech plc (TRIB) – Geschäftsmodell: Einnahmequellen

Verkauf von diagnostischen Testgeräten

Für das Geschäftsjahr 2023 meldete Trinity Biotech einen Geräteumsatz von 12,4 Millionen US-Dollar, was 35 % des Gesamtumsatzes des Unternehmens entspricht.

Ausrüstungskategorie	Jahresumsatz	Marktanteil
Klinisch-chemische Analysegeräte	6,2 Millionen US-Dollar	18%
Immunoassay-Plattformen	4,7 Millionen US-Dollar	14%
Molekulare Diagnoseinstrumente	1,5 Millionen Dollar	3%

Wiederkehrende Einnahmen aus Diagnosetestkits

Der Verkauf von Testkits generierte im Jahr 2023 wiederkehrende Einnahmen in Höhe von 22,6 Millionen US-Dollar, was 52 % des Gesamtumsatzes des Unternehmens entspricht.

• Testkits für Infektionskrankheiten: 9,3 Millionen US-Dollar
• Testkits für klinische Chemie: 8,1 Millionen US-Dollar
• Testkits für Autoimmunerkrankungen: 5,2 Millionen US-Dollar

Lizenzierung von Diagnosetechnologien

Die Technologielizenzierung generierte im Jahr 2023 einen Umsatz von 3,1 Millionen US-Dollar, was 7 % des Gesamtumsatzes des Unternehmens entspricht.

Beratungs- und technische Supportdienste

Technischer Support und Beratungsdienste trugen im Jahr 2023 1,9 Millionen US-Dollar zum Umsatz des Unternehmens bei.

Einnahmen aus der internationalen Marktexpansion

Geografische Region	Einnahmen	Wachstumsrate
Europa	8,7 Millionen US-Dollar	6.2%
Asien-Pazifik	5,4 Millionen US-Dollar	9.3%
Lateinamerika	3,2 Millionen US-Dollar	4.7%

Gesamtjahresumsatz: 43,2 Millionen US-Dollar

Trinity Biotech plc (TRIB) - Canvas Business Model: Value Propositions

You're looking at the core reasons why customers choose Trinity Biotech plc (TRIB) products right now, late in 2025. It's all about delivering high-value diagnostics that cut down on cost and complexity for both patients and the healthcare system. Here's the quick math on what we're offering.

Cost-Effective, High-Volume Rapid HIV Screening (TrinScreen HIV)

The value here centers on scalability and cost control, especially after the recent manufacturing shift. Trinity Biotech plc received World Health Organization (WHO) approval in June 2025 for the offshored and outsourced upstream manufacturing of TrinScreen HIV, a move designed to unlock significant cost efficiencies and improve scalability. This positions the product favorably in the global procurement landscape, where one reference point for a similar test was listed at USD$ 0.75. The company expected a further significant quarter-on-quarter increase in revenue in Q3, 2025, as the supply of TrinScreen HIV resumed following this approval. The 2024 sales revenue forecast for this test was previously raised to over $8 million, based on total orders for 2024 reaching $6 million.

Early, Informed Decision-Making for Severe Preeclampsia Risk (PreClara™)

For maternal health, the value proposition is early, actionable insight to prevent severe outcomes. Trinity Biotech plc announced on August 14, 2025, that its New York reference laboratory received regulatory approval from the New York State Department of Health to begin offering the FDA-cleared PreClara™ Ratio biomarker test, with service rollout planned for Q3 2025. This test targets hypertensive disorders of pregnancy, which affect approximately 500,000 women annually in the United States. Incorporating the test into standard care could potentially generate neonatal cost savings exceeding $10 million per 1,000 patients, mainly by reducing preterm deliveries and NICU admissions.

Non-Invasive, 15-Day Continuous Glucose Monitoring via CGM+

The next-generation continuous glucose monitoring (CGM+) platform offers a significant technical leap over prior versions, focusing on user experience and cost reduction. Clinical trial data confirmed the redesigned, proprietary needle-free glucose sensor delivers accurate readings across a full 15-day wear period without the need for finger-stick calibration. This addresses a major hurdle in accessibility, as the company noted that the two largest CGM manufacturers serve less than 2% of the 800 million people living with diabetes worldwide, a limitation often tied to high technology costs. The technology, acquired in 2024 for $12.5 million in cash, showed a 25-30% improvement in MARD (Mean Absolute Relative Difference) over earlier models in a trial.

Here's a snapshot of the key performance metrics for the diabetes management solution:

Metric	Value/Period	Context
Wear Period	15-day	Continuous monitoring without calibration
Accuracy Improvement (MARD)	25-30% improvement	Compared to earlier Waveform CGM sensors
Global Market Size (2025 Projection)	Approximately $13 billion	Projected to reach $28 billion by 2030
Acquisition Cost (2024)	$12.5 million in cash	Cost to acquire the initial CGM assets

Comprehensive Testing and Reduced Healthcare Costs

Trinity Biotech plc is positioning its CGM+ as a multi-metric device, moving beyond simple glucose tracking. The platform supports the single device integration of several health metrics.

The value propositions related to cost reduction are supported by the company's overall financial trajectory, driven by these product improvements and operational restructuring. Trinity Biotech plc expects to be meaningfully Adjusted EBITDA-positive and cashflow positive from ongoing operating activities starting Q3 2025. This improved profitability is built on a leaner operating foundation, which includes the cost-saving manufacturing changes for TrinScreen HIV.

The core technology features that drive cost reduction include:

• Redesigned sensor reduces disposable components
• Elimination of finger-stick calibration requirement
• Reusable and rechargeable components in CGM+
• Offshoring/outsourcing manufacturing for HIV test to reduce fixed costs

Trinity Biotech plc (TRIB) - Canvas Business Model: Customer Relationships

You're looking at how Trinity Biotech plc (TRIB) manages its connections with its diverse customer base, which spans clinical labs, public health bodies, and a growing consumer segment with its new diabetes tech. The relationship strategy is definitely multi-faceted, blending direct sales efforts with platform-based digital engagement.

Dedicated direct sales force for key accounts in North America and Europe

Trinity Biotech plc sells products directly in the U.S. and U.K., relying on a sales organization that includes leadership like the Senior Vice President Global Sales and General Manager North America, a role held since 2019. The importance of these markets is clear from the 2024 revenue breakdown, showing the Americas as a primary region, though revenues there saw a slight dip in 2024. The European market, however, showed growth in 2024.

Here's a look at the latest reported regional revenue context:

Geographic Region	Revenue (Year Ended Dec 31, 2024)	Revenue (Year Ended Dec 31, 2023)
Americas	US$29,917 thousand	US$32,282 thousand
Europe	US$6,863 thousand	US$5,641 thousand

The company noted that many of its customers rely on public funding from federal, state, and local governments, which definitely impacts the stability of these commercial relationships.

High-touch support for clinical lab instrument installation and training

For its clinical laboratory segment, the relationship is built on the delivery and maintenance of instrumentation. While specific 2025 support metrics aren't public, the company operates a New York reference laboratory offering testing services for autoimmune disorders, indicating a direct, high-touch service component for that segment.

Long-term contracts with public health authorities for HIV testing

Relationships with public health authorities are crucial, especially for the Uni-Gold HIV rapid test, a cornerstone product in international HIV screening programs. Demand from these bodies can be lumpy; for instance, sales of TrinScreen HIV reached $3.2 million in Q4 2024, contributing to a revised 2024 sales forecast of approximately $10 million for that specific test. Uncertainty around U.S. government HIV test funding caused production pullbacks in Q1 2025.

A major recent development in this relationship area is the November 2025 World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing of the Uni-Gold HIV test. This transition, which took approximately two years to develop, is expected to improve gross margin, EBITDA, and cashflow generation, streamlining operations for these key public health customers.

Digital engagement and real-time analytics for the CGM+ consumer base

The relationship model shifts significantly with the next-generation Continuous Glucose Monitoring (CGM) solution, CGM+. This platform is designed for the $260 billion AI wearables market, targeting both diabetes patients and health-conscious consumers. The engagement model is centered on recurring revenue potential through AI analytics subscriptions.

Key performance indicators from the redesigned sensor in pre-pivotal testing highlight the value proposition driving this engagement:

• No finger-stick calibration required over a full 15-day sensor wear period.
• Approximately 35% better Mean Absolute Relative Difference (MARD) compared to the prior Waveform product.
• More than 50% improvement in Mean Absolute Difference (MAD) over the prior Waveform product.

The trial involved 30 participants, primarily with Type 1 diabetes. Trinity Biotech plc anticipates commercial launch of CGM+ in mid-2026, with a U.S. FDA filing planned for 2026.

Regulatory compliance and quality assurance to maintain trust (defintely crucial)

Maintaining trust is non-negotiable, especially when dealing with diagnostic products and medical devices. The recent WHO approval for the Uni-Gold HIV test manufacturing change explicitly states the company will retain the highest levels of product integrity and regulatory compliance during the transition. This focus on compliance is the bedrock for all customer relationships, from public health bodies to individual CGM users.

The company's Q1 2025 revenue estimate of US$7.0 million to US$8.0 million was substantially below Q1 2024, partly due to deferred manufacturing while changing locations, underscoring how operational changes tied to quality and location impact commercial flow.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Channels

You're looking at how Trinity Biotech plc gets its diagnostic products and services into the hands of healthcare providers as of late 2025. The channel strategy clearly splits based on geography and product type, which is typical for a company with a diverse portfolio spanning central labs and point-of-care.

Direct sales teams targeting hospitals and reference laboratories form the backbone of their presence in key, high-value markets. Trinity Biotech plc serves a worldwide customer base through direct sales operations specifically in North America and Europe. This direct approach is used for certain high-value instruments, such as the Premier Hb9210 HbA1c analyzer, in the USA and Brazil. The clinical laboratory segment, which relies on these direct channels for service and support, generated revenues of $44.1m for the full year ended December 31, 2024. The company's Q1 2025 revenue guidance was between US$7.0 million to US$8.0 million, reflecting a transitional period where manufacturing ramp-up impacts immediate channel fulfillment.

The network of independent distributors across Asia Pacific and the Middle East, along with Latin America, handles much of the international reach for Trinity Biotech plc. This distributor model is employed for the Premier Hb9210 in the rest of the world outside the direct sales territories. The company's success is highly dependent on servicing and supporting products through these strategic partners. For instance, in the Middle East, distributors like GULF PHARMACY AND GENERAL STORE in Bahrain and Ronoc TEB in Iran are listed as channel partners. In Asia Pacific, Progressive International Holding Co Ltd in China and Biozen in Thailand represent this distribution layer.

Here's a look at the revenue segmentation from the most recently reported full fiscal year, which gives you a sense of the scale each major channel grouping supports:

Channel/Segment Focus	FY 2024 Revenue (USD)	FY 2024 Revenue Percentage (of $61.6m TTM)
Clinical Laboratory (Mix of Direct/Distributor)	$44.1m	Approx. 71.6%
Point-of-Care (PoC) (Mix of Direct/Distributor)	$17.5m (Calculated: $61.6m - $44.1m)	Approx. 28.4%

Reference laboratory services for specialized testing (e.g., PreClara™) are a key part of the Clinical Laboratory channel. Trinity Biotech plc received regulatory approval to begin its FDA-cleared PreClara™ Preeclampsia Testing Service, positioning this specialized offering within the reference lab channel. The overall Clinical Laboratory revenues for FY 2024 were $44.1m, a decrease of 7.6% year-on-year from $47.7m in FY 2023. The company also provides raw materials to the life sciences industry globally, which is another service-based revenue stream.

The online and app-based platform for the CGM+ wearable biosensor represents a future-facing channel, though concrete 2025 sales data is not yet public. Trinity Biotech plc is actively analyzing results from pre-pivotal testing on its updated CGM sensor, which promises a 15-day usage period without recalibration. This technology is designed to transform glucose monitoring into a seamless, fingertip-free experience, suggesting a future direct-to-consumer or direct-to-clinic digital sales/subscription component, though the current focus remains on development and regulatory milestones.

Global tenders and procurement processes for public health products are critical for high-volume sales of rapid tests, such as the TrinScreen HIV test. The company secured regulatory approval for its offshored and outsourced manufacturing of its flagship rapid HIV test, which is expected to underpin a significant quarter-on-quarter revenue increase in Q3, 2025, following WHO approval. Sales of TrinScreen HIV were $10.0m for the full year 2024, up from $0.4m in 2023, showing the impact of large-scale procurement channels.

• Direct Sales Focus: North America and Europe.
• Distributor Focus: Asia Pacific, Latin America, and the Middle East.
• Direct Sales for Premier Hb9210: USA and Brazil.
• FY 2024 Clinical Lab Revenue: $44.1m.
• FY 2024 TrinScreen HIV Sales: $10.0m.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Customer Segments

You're looking at the core groups Trinity Biotech plc (TRIB) serves with its diagnostic and diabetes management portfolio. Honestly, it's a diverse set of buyers, ranging from large centralized labs to individual patients managing chronic conditions. The company markets its several hundred products to customers in approximately 100 countries globally. A majority of the revenue is derived from the Americas segment.

Here's a breakdown of the distinct customer segments Trinity Biotech plc targets:

• Clinical and reference laboratories globally
• Public health authorities and NGOs (e.g., for HIV screening)
• Hospitals and clinics focused on maternal health (preeclampsia testing)
• Diabetics and healthcare providers for continuous glucose monitoring
• Life sciences and research industries (raw materials supply)

The scale of the business, based on late 2024 financials, shows a trailing twelve-month revenue of $61.6M. The company expected Q1 2025 revenue to be between US$7.0 million to US$8.0 million, with a ramp-up expected by late Q2 to Q3 2025.

The primary customer groups and relevant data points are detailed below:

Customer Segment	Key Trinity Biotech Offering	Relevant Market/Customer Data
Clinical and Reference Laboratories	In vitro diagnostic systems, reagents, instrumentation, Immco lab services	Diagnostic laboratories accounted for the highest market share of 45.9% in the global HIV diagnostics market in 2024. Trinity Biotech sells directly in the United States, Brazil, Germany, France, and the U.K..
Hospitals and Clinics (Maternal Health Focus)	FDA-cleared PreClara Ratio (sFlt-1/PlGF) biomarker test service	The service targets hypertensive disorders of pregnancy, which impact approximately 500,000 women in the United States every year. Incorporation of the test could yield neonatal cost savings exceeding $10 million per 1,000 patients.
Public Health Authorities and NGOs	Uni-Gold™ HIV rapid test, TrinScreen HIV	The global HIV diagnostics market was projected at $2.6 billion in 2025. Trinity Biotech's Uni-Gold test received WHO approval in November 2025 for its outsourced manufacturing. TrinScreen HIV sales were $3.2M in Q4 2024.
Diabetics and Healthcare Providers	Wearable biosensors, Continuous Glucose Monitoring (CGM) product development, Hemoglobin A1c analyzers	Trinity Biotech entered the biosensor industry with the acquisition of Waveform Technologies Inc.'s assets to develop a CGM product. Products quantify the level of Haemoglobin A1c.
Life Sciences and Research Industries	Raw materials supply	Trinity Biotech plc provides raw materials to the life sciences and research industries globally.

For infectious disease testing, Trinity Biotech plc offers serological and rapid tests for diseases like HIV and hepatitis B and C, used by these facilities to support diagnosis and treatment monitoring. The Point-of-Care (PoC) portfolio generated revenue of $5.5M for Q4 2024.

The company's strategy involves direct sales in key markets like the US, and a distributor network covering the rest of the world. You should note that the clinical laboratory revenue segment saw a decrease of $3.6M year-over-year for the full year 2024, down to $44.1M.

The focus on maternal health with the PreClara Ratio test, launched in Q3 2025, is a strategic move to enhance the position in a critical clinical area. Also, the company is working on PrePsia™, its proprietary preeclampsia risk assessment technology for early pregnancy, with first revenues expected in 2025 following the September 2024 acquisition of Metabolomics Diagnostics.

For the HIV segment, the company is streamlining operations, with the outsourcing of Uni-Gold™ manufacturing expected to improve gross margins and EBITDA. Finance: review the Q1 2025 actuals against the $7.0M - $8.0M projection by end of next week.

Trinity Biotech plc (TRIB) - Canvas Business Model: Cost Structure

You're looking at the expenses Trinity Biotech plc is managing as it pushes through its transformation plan. Honestly, the cost structure is dominated by the core business of manufacturing diagnostics and the heavy investment needed for the new Continuous Glucose Monitoring (CGM) platform.

The most significant component is the Cost of Goods Sold (COGS), which reflects the direct costs of producing their diagnostic kits and reagents. For the full twelve months ended December 31, 2024, the Cost of Sales was reported at $40,114 thousand, up from $37,382 thousand in 2023. This shows the pressure from raw materials and manufacturing scale, even as they work on efficiencies.

To drive future savings, Trinity Biotech plc took a hit in 2024. They incurred restructuring and other one-off costs totaling $6.1 million for the year ended December 31, 2024. This was part of the Comprehensive Transformation Plan to consolidate and offshore manufacturing and corporate services. The company expects this aggressive restructuring to lead to a leaner cost base, projecting they will be meaningfully Adjusted EBITDA positive and cash flow positive from ongoing operating activities starting in the third quarter of 2025. For context on the quarterly impact, Q4 2024 included restructuring, impairment, and one-off costs totaling $4.7 million.

Research and development (R&D) remains a key cost area, particularly for the new CGM technology. For the full year 2024, Research and development expenses were US$4.5 million, a slight increase from US$4.4 million in 2023. You see this investment flow into assets, too; for instance, the largest element of investing cash outflows in Q4 2024, at $2.7 million, pertained to the capitalization of development costs for their CGM device.

The Selling, General, and Administrative (SG&A) expenses reflect the cost of supporting the global sales teams across over 75 countries. For the full year 2024, SG&A was $28.8 million, which was a favorable decrease of $2.3 million compared to 2023, driven by organizational realignment measures.

Financing costs are tied to the debt load. While you mentioned approximately $100.8 million, the balance sheet as of December 2024 showed total debt of $0.10 Billion USD. The Net financing expense for the full year 2024 was $9.6 million, down from $9.9 million in 2023.

Here's a quick look at the major expense lines for the full year 2024 compared to 2023 (all figures in US$000s unless noted):

Cost Category	Twelve Months Ended Dec 31, 2024 (US$000's)	Twelve Months Ended Dec 31, 2023 (US$000's)
Cost of Sales	(40,114)	(37,382)
Research & development expenses	4,500	4,400
Selling, general and administrative expenses	28,800	31,100
Restructuring and other once off costs	6,100	0
Net financing expense	9,600	9,900

The operational focus is clearly on cost reduction, as evidenced by the SG&A decrease and the restructuring charges. You can see the impact of the transformation plan in the quarterly figures, too:

• SG&A expenses in Q3 2024 were $6.5 million, down from $7.7 million in Q3 2023.
• SG&A expenses in Q2 2024 were $6.4 million, down from $7.9 million in Q2 2023.
• The company is exiting sub-scale, lower-margin third-party product lines that previously generated approximately $3 million in annual revenue in 2024.
• The Senior secured term loan component of non-current liabilities was $72,391 thousand as of December 31, 2024.

If onboarding for the new manufacturing structure takes longer than expected, churn risk rises.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Revenue Streams

You're looking at the core ways Trinity Biotech plc brings in money right now, as of late 2025. It's a mix of established diagnostics and newer, high-potential areas, especially as they exit their restructuring phase.

The primary, immediate revenue sources are tied to the sales of clinical laboratory products and instrumentation, alongside their Point-of-Care (PoC) offerings. For the trailing twelve months ending in December 2025, Trinity Biotech plc's total revenue stands at approximately $61.55 Million USD. This figure reflects the ramp-up following operational changes.

Looking at recent quarterly performance gives you a clearer picture of the momentum. For instance, Q1 2025 revenue was reported at $7.6 million. Management projected a significant sequential jump for Q2 2025, guiding revenue to a range of $11 million to $12 million. This growth was expected to be driven by normalized demand for their rapid HIV tests and stabilized manufacturing.

The Point-of-Care (PoC) segment is a key driver, notably through the TrinScreen HIV test. While the full-year 2024 guidance for TrinScreen HIV sales was set around $10 million, Q4 2024 saw sales of $3.2 million for that specific test alone. The company had previously targeted an annualized run rate revenue of around $75 million by Q2 2025 based on Q3 2024 projections.

Here's a breakdown of the revenue components based on the most recent segment data available:

Revenue Stream Category	Specific Metric/Period	Amount
Trailing 12-Month Revenue (TTM)	As of December 2025	$61.55 Million USD
Projected Quarterly Revenue	Q2 2025 Range	$11 million to $12 million
Reported Quarterly Revenue	Q1 2025	$7.6 million
Point-of-Care (PoC) Revenue	Q4 2024	$5.5 million
Clinical Laboratory Revenue	Q4 2024	$10.3 million
TrinScreen HIV Sales	Q4 2024	$3.2 million

Beyond the immediate diagnostics, Trinity Biotech plc is positioning for future recurring revenue, particularly in diabetes management. The next-generation Continuous Glucose Monitoring (CGM+) platform, though anticipated for commercial launch in mid-2026, is designed to open multiple revenue streams.

Future revenue potential is clearly mapped out:

• Device sales from the CGM+ platform.
• AI analytics subscriptions and related services tied to the CGM+ system.
• Revenue from the preeclampsia test, which was expected to start generating revenue in the second half of 2025.
• Strategic partnerships with healthcare providers and insurers related to the new biosensor technology.

The successful WHO approval for offshored manufacturing of TrinScreen HIV is also set to underpin further revenue increases starting in Q3 2025.